Data from several studies suggest that suppressed DGAT1 is a promising strategy to inhibit prostate cancer cell growth and, therefore, targeting DGAT1 might be conducive for clinical gastric cancer treatment [12, 13]. The gene discussed is DGAT1; the disease is prostate cancer.